<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04661150</url>
  </required_header>
  <id_info>
    <org_study_id>ML42058</org_study_id>
    <nct_id>NCT04661150</nct_id>
  </id_info>
  <brief_title>A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction</brief_title>
  <official_title>A Phase II, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) and Trastuzumab in Combination With Capecitabine and Oxaliplatin (Xelox) in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction (GEJ)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, multicenter, randomized, open-label study designed to evaluate the&#xD;
      efficacy and safety of perioperative trastuzumab+XELOX with / without atezolizumab in&#xD;
      participants eligible for surgery with locally advanced HER2-positive gastric cancer or&#xD;
      adenocarcinoma of GEJ.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological Complete Regression (pCR) Rate</measure>
    <time_frame>Completion of neoadjuvant systemic therapy (up to approximately 16 months)</time_frame>
    <description>pCR is defined as no evidence of vital residual tumor cells on hematoxylin and eosin evaluation of the complete resected gastric/GEJ specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy (NAST), which will be reviewed by local pathologist..</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>Randomization to the first documented disease recurrence, unequivocal tumor progression or death from any cause, whichever occurs first (up to approximately 52 months)</time_frame>
    <description>Event-free survival (EFS), defined as the time from randomization to the first documented disease recurrence, unequivocal tumor progression determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Survival (DFS)</measure>
    <time_frame>Surgery to first documented disease recurrence or death from any cause, whichever occurs first (up to approximately 52 months)</time_frame>
    <description>Disease-free survival (DFS), defined as the time from surgery to the first documented disease recurrence or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Randomiation to death from any cause (up to approximately 52 months)</time_frame>
    <description>Overall survival (OS), defined as the time from randomization to death from any cause in all patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Pathologic Response (MPR)</measure>
    <time_frame>Randomization up to approximately 16 months</time_frame>
    <description>Major pathologic response (MPR), defined as &lt; 10% residual tumor per tumor bed based on evaluation of the resected primary esophagogastric specimen by a local pathologist.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Randomiation to CR or PR during neoadjuvant systemic therapy (up to approximately 16 months)</time_frame>
    <description>Objective response rate (ORR), defined as the proportion of patients with a complete response (CR) or partial response (PR) during NAST, as determined by the investigator according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 Resection Rate</measure>
    <time_frame>Surgery</time_frame>
    <description>R0 resection rate, defined as the proportion of patients with a microscopically margin-negative resection, in which no gross or microscopic tumor remains in the primary tumor bed and/or sampled regional lymph nodes based on evaluation by the local pathologist.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>Baseline through the end of study (approximately 52 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A: Atezolizumab plus Trastuzumab with XELOX (Capecitabine + Oxaliplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive atezolizumab + trastuzumab + XELOX (Capecitabine + Oxaliplatin) for 3 treatment cycles prior to surgery, each cycle is 3 weeks. Following surgery, patrticipants will receive 5 further cycles of this regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Trastuzumab with XELOX (Capecitabine + Oxaliplatin)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive trastuzumab + XELOX (Capecitabine + Oxaliplatin) for 3 treatment cycles prior to surgery, each cycle is 3 weeks. Following surgery, participants will receive 5 further cycles of this regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle for 3 cycles prior to surgery and 5 cycles after surgery.</description>
    <arm_group_label>Arm A: Atezolizumab plus Trastuzumab with XELOX (Capecitabine + Oxaliplatin)</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Trastuzumab will be administered as an 8 mg/kg IV loading dose and then 6 mg/kg IV on Day 1 of a 21-day cycle for 3 cycles before surgery, and administration will continue after surgery. The first administration of trastuzumab after surgery should also be given at the loading dose of 8 mg/kg.</description>
    <arm_group_label>Arm A: Atezolizumab plus Trastuzumab with XELOX (Capecitabine + Oxaliplatin)</arm_group_label>
    <arm_group_label>Arm B: Trastuzumab with XELOX (Capecitabine + Oxaliplatin)</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 1000 mg/m^2 will be administered twice orally on Days 1-14, repeated every 3 weeks.</description>
    <arm_group_label>Arm A: Atezolizumab plus Trastuzumab with XELOX (Capecitabine + Oxaliplatin)</arm_group_label>
    <arm_group_label>Arm B: Trastuzumab with XELOX (Capecitabine + Oxaliplatin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin 130 mg/m^2 will be administered by IV on Day 1 of a 21-day cycle.</description>
    <arm_group_label>Arm A: Atezolizumab plus Trastuzumab with XELOX (Capecitabine + Oxaliplatin)</arm_group_label>
    <arm_group_label>Arm B: Trastuzumab with XELOX (Capecitabine + Oxaliplatin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed gastric cancer or adenocarcinoma of GEJ&#xD;
&#xD;
          -  HER2-positive status defined as either IHC score of 3+ or IHC 2+ with amplification&#xD;
             proven by in situ hybridization (ISH) as assessed by local review based on&#xD;
             pretreatment endoscopic biopsies.&#xD;
&#xD;
          -  Clinical stage at presentation: cT3/T4a/T4b, or N+, M0 as determined by AJCC staging&#xD;
             system, 8th edition&#xD;
&#xD;
          -  Availability of pretreatment tumor specimen for biomarker analysis by central lab&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Life expectancy &gt;= 12 weeks&#xD;
&#xD;
          -  Adequate hematologic and end-organ function&#xD;
&#xD;
          -  For female patients of childbearing potential, agreement (by patient) to remain&#xD;
             abstinent (refrain from heterosexual intercourse) or to use highly effective form(s)&#xD;
             of contraception during the treatment period and to continue its use for at least i) 5&#xD;
             months after the last dose of atezolizumab, ii) 7 months after the last dose of&#xD;
             trastuzumab, or iii) 6 months after the last dose of capecitabine or oxaliplatin,&#xD;
             whichever is longer.&#xD;
&#xD;
          -  For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use&#xD;
             a condom, and agreement to refrain from donating sperm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stage IV (metastatic) or unresectable gastric/GEJ cancer determined by investigators&#xD;
&#xD;
          -  Prior systemic therapy for treatment of gastric cancer&#xD;
&#xD;
          -  History of malignancy other than GC within 5 years prior to screening, with the&#xD;
             exception of malignancies with a negligible risk of metastasis or death&#xD;
&#xD;
          -  Cardiopulmonary dysfunction&#xD;
&#xD;
          -  Dyspnea at rest&#xD;
&#xD;
          -  Active or history of autoimmune disease or immune deficiency with the following&#xD;
             exceptions: (a) Patients with a history of autoimmune-mediated hypothyroidism who are&#xD;
             on thyroid-replacement hormone are eligible for the study. (b) Patients with&#xD;
             controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the&#xD;
             study. (c) Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with&#xD;
             dermatologic manifestations only are eligible for the study provided allof following&#xD;
             conditions are met: (i) Rash must cover &lt; 10% of body surface area (ii) Disease is&#xD;
             well controlled at baseline and requires only low-potency topical corticosteroids&#xD;
             (iii) No occurrence of acute exacerbations of the underlying condition requiring&#xD;
             psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral&#xD;
             calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12&#xD;
             months&#xD;
&#xD;
          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced&#xD;
             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening&#xD;
             chest CT scan&#xD;
&#xD;
          -  Active tuberculosis&#xD;
&#xD;
          -  Patients with active hepatitis B&#xD;
&#xD;
          -  Patients with active hepatitis C&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: ML42058 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global.rochegenentechtrials@roche.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University; Department of Breast</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital</name>
      <address>
        <city>Hangzhou</city>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center; Medical Oncology</name>
      <address>
        <city>Shanghai City</city>
        <zip>201315</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Liaoning Provincial Cancer Hospital</name>
      <address>
        <city>Shengyang</city>
        <zip>110042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>First Hospital of China Medical University; Surgery</name>
      <address>
        <city>Shenyang City</city>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute &amp; Hospital</name>
      <address>
        <city>Tianjing</city>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Zhejiang</city>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>December 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2020</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here ( https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

